One-Time Marketing Status Reports Due in February, FDA Says
By Zachary Brennan -
Published 03 January 2018
The US Food and Drug Administration (FDA) is calling on all new drug application (NDA) and abbreviated new drug application (ANDA) holders to submit one-time written reports on whether their products are available for sale or if they have been withdrawn or were never made available for sale.
Categories: News, US, FDA, Drugs, Regulatory intelligence, Regulatory strategy, Submission and registration
Tags: marketing status, user fee, FDARA, FDA status reports